MicroTransponder
Series F in 2025
MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating various neurological diseases. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation (VNS) to address conditions such as tinnitus, chronic pain, and rehabilitation for stroke survivors. Its notable products include the Serenity System, designed specifically for tinnitus treatment, and the Vivistim device, which is FDA approved for assisting ischemic stroke survivors with moderate to severe upper limb impairment. Through its innovative approaches, MicroTransponder aims to enhance recovery and improve the quality of life for individuals affected by these neurological conditions.
Saluda Medical
Venture Round in 2025
Saluda Medical Pty Ltd. is a medical device company specializing in the development of neuromodulation technologies for chronic neurological conditions. Founded in 2010 and based in Artarmon, Australia, with additional offices in the United States and the United Kingdom, Saluda Medical focuses on its innovative Evoke system. This investigational device employs a closed-loop spinal cord stimulation approach that continuously monitors the spinal cord's response to stimulation and adjusts treatment in real-time to optimize patient outcomes. By utilizing a unique dose-control platform, Saluda Medical aims to customize therapy based on individual neural responses, thereby improving the management of chronic pain, particularly in patients suffering from conditions such as neuropathic pain and chronic back pain.
NeuSpera Medical
Series D in 2024
NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.
Presidio Medical
Series C in 2023
Presidio Medical, Inc. is a clinical-stage medical device company based in South San Francisco, California, founded in 2017. The company specializes in developing a transformative neuromodulation technology platform aimed at treating chronic pain and other disorders related to neuronal activity. By employing biotechnology, Presidio Medical seeks to create bioelectronic medicine solutions that establish a new class of therapeutic devices, ultimately providing patients with effective remedies for various neural-related conditions.
Saluda Medical
Venture Round in 2023
Saluda Medical Pty Ltd. is a medical device company specializing in the development of neuromodulation technologies for chronic neurological conditions. Founded in 2010 and based in Artarmon, Australia, with additional offices in the United States and the United Kingdom, Saluda Medical focuses on its innovative Evoke system. This investigational device employs a closed-loop spinal cord stimulation approach that continuously monitors the spinal cord's response to stimulation and adjusts treatment in real-time to optimize patient outcomes. By utilizing a unique dose-control platform, Saluda Medical aims to customize therapy based on individual neural responses, thereby improving the management of chronic pain, particularly in patients suffering from conditions such as neuropathic pain and chronic back pain.
Onc.AI, Inc. is a technology company founded in 2020 and headquartered in San Carlos, California. It specializes in clinical oncology, utilizing advanced software that integrates genomics, proteomics, and radiomics to enhance oncology diagnostics. By employing deep learning techniques, Onc.AI aims to provide actionable insights that improve treatment outcomes for cancer patients. The company's innovative approach seeks to advance the field of oncology through the development of comprehensive data-driven solutions.
Alpheus Medical
Series A in 2022
Alpheus Medical specializes in innovative treatments for solid body cancers, focusing on a sonodynamic therapy platform. The company has developed a non-invasive drug-device combination specifically designed for the outpatient treatment of recurrent glioblastoma multiforme, an aggressive form of brain cancer. Utilizing photodynamic therapy, Alpheus Medical's surgical device delivers light to target cancer cells that have been treated with a photosensitizer, allowing patients to receive effective treatment while avoiding the need for invasive brain surgery. This approach underscores the company's commitment to improving patient outcomes through advanced medical technologies.
MicroTransponder
Series E in 2022
MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating various neurological diseases. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation (VNS) to address conditions such as tinnitus, chronic pain, and rehabilitation for stroke survivors. Its notable products include the Serenity System, designed specifically for tinnitus treatment, and the Vivistim device, which is FDA approved for assisting ischemic stroke survivors with moderate to severe upper limb impairment. Through its innovative approaches, MicroTransponder aims to enhance recovery and improve the quality of life for individuals affected by these neurological conditions.
Alpheus Medical
Series A in 2021
Alpheus Medical specializes in innovative treatments for solid body cancers, focusing on a sonodynamic therapy platform. The company has developed a non-invasive drug-device combination specifically designed for the outpatient treatment of recurrent glioblastoma multiforme, an aggressive form of brain cancer. Utilizing photodynamic therapy, Alpheus Medical's surgical device delivers light to target cancer cells that have been treated with a photosensitizer, allowing patients to receive effective treatment while avoiding the need for invasive brain surgery. This approach underscores the company's commitment to improving patient outcomes through advanced medical technologies.
NeuSpera Medical
Series C in 2021
NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.
Exo is a medical device startup focused on revolutionizing ultrasound technology for imaging and therapeutic applications. The company has developed a handheld ultrasound platform that integrates advanced nano-materials, innovative sensor technologies, and sophisticated signal processing with the cost advantages of semiconductor manufacturing. This approach allows Exo to provide high-quality, affordable, and user-friendly medical imaging solutions. By enabling healthcare professionals to make critical, real-time decisions, Exo aims to enhance patient outcomes significantly. The company's commitment to accessibility and ease of use in medical imaging represents a significant advancement in the field, making effective diagnostic tools available at an unprecedented price point.
Presidio Medical
Series B in 2020
Presidio Medical, Inc. is a clinical-stage medical device company based in South San Francisco, California, founded in 2017. The company specializes in developing a transformative neuromodulation technology platform aimed at treating chronic pain and other disorders related to neuronal activity. By employing biotechnology, Presidio Medical seeks to create bioelectronic medicine solutions that establish a new class of therapeutic devices, ultimately providing patients with effective remedies for various neural-related conditions.
CVRx
Venture Round in 2020
CVRx, Inc. is a medical device company headquartered in Minneapolis, Minnesota, that specializes in the development of implantable technologies for the treatment of high blood pressure and heart failure. Founded in 2000, the company has created Barostim NEO, a neuro-modulation therapy that activates the body's natural mechanisms to regulate blood pressure and address heart failure progression. This therapy utilizes an implantable system that is tailored to the individual needs of patients. CVRx also offers the Rheos platform, which includes an implantable pulse generator and carotid sinus leads designed to deliver therapeutic energy to the carotid arteries. With a focus on minimally invasive solutions, CVRx primarily serves patients and healthcare professionals in the United States and internationally, including markets in the United Kingdom, the Netherlands, Italy, and Germany.
SetPoint Medical
Venture Round in 2019
SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for the treatment of debilitating inflammatory diseases. Established in 2006 and formerly known as Innovative Metabolics Inc., the company aims to provide innovative solutions for chronic autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease. SetPoint Medical's technology leverages vagus nerve stimulation to activate the body's natural inflammatory reflex, producing a systemic anti-inflammatory effect. This platform offers an alternative treatment option that may present lower risks and costs compared to traditional drug therapies, ultimately seeking to improve patient outcomes in managing chronic inflammatory diseases.
Axon Therapies
Series A in 2019
Axon Therapies is a healthcare company focused on developing innovative solutions to address heart failure by targeting the sympathetic nervous system. The company has created the SAVM procedure, which utilizes a specialized device that allows clinicians to ablate the right greater splanchnic nerve through a minimally invasive catheter inserted via the groin. This procedure aims to reduce sympathetic nerve activity, restore balance in the circulatory system, and shift blood volume away from the heart, ultimately lowering heart pressures. By enabling rapid intervention, Axon Therapies enhances the likelihood of successful treatment outcomes for patients suffering from heart failure.
CVRx, Inc. is a medical device company headquartered in Minneapolis, Minnesota, that specializes in the development of implantable technologies for the treatment of high blood pressure and heart failure. Founded in 2000, the company has created Barostim NEO, a neuro-modulation therapy that activates the body's natural mechanisms to regulate blood pressure and address heart failure progression. This therapy utilizes an implantable system that is tailored to the individual needs of patients. CVRx also offers the Rheos platform, which includes an implantable pulse generator and carotid sinus leads designed to deliver therapeutic energy to the carotid arteries. With a focus on minimally invasive solutions, CVRx primarily serves patients and healthcare professionals in the United States and internationally, including markets in the United Kingdom, the Netherlands, Italy, and Germany.
NeuSpera Medical
Series B in 2019
NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.
NeuSpera Medical
Series B in 2018
NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.
Presidio Medical
Series A in 2018
Presidio Medical, Inc. is a clinical-stage medical device company based in South San Francisco, California, founded in 2017. The company specializes in developing a transformative neuromodulation technology platform aimed at treating chronic pain and other disorders related to neuronal activity. By employing biotechnology, Presidio Medical seeks to create bioelectronic medicine solutions that establish a new class of therapeutic devices, ultimately providing patients with effective remedies for various neural-related conditions.
SetPoint Medical
Series D in 2017
SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for the treatment of debilitating inflammatory diseases. Established in 2006 and formerly known as Innovative Metabolics Inc., the company aims to provide innovative solutions for chronic autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease. SetPoint Medical's technology leverages vagus nerve stimulation to activate the body's natural inflammatory reflex, producing a systemic anti-inflammatory effect. This platform offers an alternative treatment option that may present lower risks and costs compared to traditional drug therapies, ultimately seeking to improve patient outcomes in managing chronic inflammatory diseases.
Saluda Medical
Series D in 2017
Saluda Medical Pty Ltd. is a medical device company specializing in the development of neuromodulation technologies for chronic neurological conditions. Founded in 2010 and based in Artarmon, Australia, with additional offices in the United States and the United Kingdom, Saluda Medical focuses on its innovative Evoke system. This investigational device employs a closed-loop spinal cord stimulation approach that continuously monitors the spinal cord's response to stimulation and adjusts treatment in real-time to optimize patient outcomes. By utilizing a unique dose-control platform, Saluda Medical aims to customize therapy based on individual neural responses, thereby improving the management of chronic pain, particularly in patients suffering from conditions such as neuropathic pain and chronic back pain.
Cala Health
Series B in 2016
Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. The company specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. Its flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on individualized peripheral nerve stimulation to enhance patient outcomes. In addition to its work on essential tremor, the company is also developing therapies for conditions such as Parkinson's disease, as well as exploring applications in psychiatry, cardiology, and autoimmune disorders.
SetPoint Medical
Series C in 2015
SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for the treatment of debilitating inflammatory diseases. Established in 2006 and formerly known as Innovative Metabolics Inc., the company aims to provide innovative solutions for chronic autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease. SetPoint Medical's technology leverages vagus nerve stimulation to activate the body's natural inflammatory reflex, producing a systemic anti-inflammatory effect. This platform offers an alternative treatment option that may present lower risks and costs compared to traditional drug therapies, ultimately seeking to improve patient outcomes in managing chronic inflammatory diseases.
SetPoint Medical
Series C in 2013
SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for the treatment of debilitating inflammatory diseases. Established in 2006 and formerly known as Innovative Metabolics Inc., the company aims to provide innovative solutions for chronic autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease. SetPoint Medical's technology leverages vagus nerve stimulation to activate the body's natural inflammatory reflex, producing a systemic anti-inflammatory effect. This platform offers an alternative treatment option that may present lower risks and costs compared to traditional drug therapies, ultimately seeking to improve patient outcomes in managing chronic inflammatory diseases.
Alpheus Medical specializes in innovative treatments for solid body cancers, focusing on a sonodynamic therapy platform. The company has developed a non-invasive drug-device combination specifically designed for the outpatient treatment of recurrent glioblastoma multiforme, an aggressive form of brain cancer. Utilizing photodynamic therapy, Alpheus Medical's surgical device delivers light to target cancer cells that have been treated with a photosensitizer, allowing patients to receive effective treatment while avoiding the need for invasive brain surgery. This approach underscores the company's commitment to improving patient outcomes through advanced medical technologies.